- A phase 2a basket study found that the combination of pertuzumab and trastuzumab produced a 23% response rate in HER2 + metastatic biliary cancer.
Why this matters
- There are few available treatments for this population.
- Nonrandomized, multicenter, open-label, phase 2a basket study (MyPathway, n=39).
- Funding: F. Hoffmann-La...